The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Drug development is a high-stakes, high-cost endeavour. Every new drug entering clinical trials requires careful decision-making, particularly regarding trial design and resource allocation.

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D, as the company faces down criticism of its recent efforts to develop and build its pipeline. He is ...

UnitedHealth chief executive Brian Thompson, who was shot dead in a Manhattan street yesterday, received death threats that may have related to "a lack of coverage", according to his widow.

Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact. Here, Alpharmaxim’s William Hind ...

Like many industries, the pharmaceutical labour market has felt and will continue to feel the impacts of the COVID-19 pandemic moving into 2023 and beyond. A new operating model for pharma shifted ...